İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2026

Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h Infusions

Medicina

YÖKSİS OpenAlex ISSN 1648-9144 DOI 10.3390/medicina62050987 Atıf 0 Açık erişim · gold SJR Q2 · 2025 JCR Q1 · 2025

10.3390/medicina62050987

YÖKSİS YÖKSİS makale kaydı

OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

OpenAlex kaydı

İngilizce (OpenAlex)

Background and Objectives: FLOT is a highly effective first-line treatment for metastatic gastric cancer and offers a favorable safety profile. Clinical studies investigating the FLOT regimen have reported varying outcomes depending on the infusion duration and have highlighted possible differences in complication rates and the efficacy of neoadjuvant therapy. The choice between 24 h or 48 h infusion durations for fluorouracil can be influenced by several factors, such as the patient’s overall health status, their tolerance to treatment, and the specific treatment protocol determined by the medical team. In this study, we aimed to evaluate the effects of different infusion durations (24 and 48 h) on clinical response, toxicity, and survival in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. Materials and Methods: This retrospective multicenter study included 113 patients with gastric or gastroesophageal junction adenocarcinoma who received neoadjuvant FLOT chemotherapy (24 h infusion: n = 28; 48 h infusion: n = 85). Propensity score matching (PSM) was performed to balance baseline characteristics, yielding a matched cohort of 90 patients. The primary endpoints were the pathologic complete response (pCR) and toxicity. Secondary endpoints included disease-free survival (DFS) and overall survival (OS). Results: Significant baseline imbalances existed (cT stage p < 0.001). After PSM, the balance improved (cT stage p = 0.009). In the matched cohort, pCR 11.1% (24 h) vs. 12.1% (48 h), p > 0.99. The median DFS was 27.4 mo (24 h) vs. NR (48 h), p = 0.847. The median OS was 32.8 mo in both, p = 0.797. Multivariate analysis (baseline variables) indicates that infusion duration is not prognostic (DFS HR = 0.77, p = 0.453; OS HR = 0.72, p = 0.328). Power was ~10% for a 1% pCR difference. Conclusions: The 24 h infusion protocol was associated with similar outcomes to the 48 h protocol after PSM adjustment. However, residual confounding persists (cT stage p = 0.009 despite PSM), and the combination of this study’s retrospective design and severe underpowering (~10%) precludes definitive conclusions. As a result, the findings are hypothesis-generating.

OpenAlex zenginleştirmesi

Konular

  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Intraperitoneal and Appendiceal Malignancies

Tür: article Gastric Cancer Management and Outcomes

İndeks bilgisi

WoS (JCR) ve Scopus (SJR) çeyrekleri ISSN ve yayın yılına göre. · 2026

Scopus (SJR) / WoS (JCR)

Medicina (Lithuania)

Scopus (SJR) Q2 0,742 En yakın yıl: 2025

Makale yılı 2026; gösterilen indeks yılı 2025.

WoS (JCR) Q1 JIF 2,9 En yakın yıl: 2025

Makale yılı 2026; gösterilen indeks yılı 2025.

Üniversiteler

  • AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
  • ALANYA ALAADDİN KEYKUBAT ÜNİVERSİTESİ

Yazarlar

  1. HACER DEMİR AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
  2. CANAN YILDIZ
  3. YUSUF İLHAN
  4. MURAT ARAZ
  5. ALİ FUAT GÜRBÜZ
  6. SEMİHA URVAY
  7. MUSLİH ÜRÜN
  8. BERRAK MERMİT ERÇEK
  9. ONUR YAZDAN BALÇIK
  10. BEYZA ÜNLÜ
  11. SENA ECE DAVARCI
  12. RAMAZAN COŞAR
  13. MELTEM BAYKARA AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
  14. İSMAİL BEYPINAR ALANYA ALAADDİN KEYKUBAT ÜNİVERSİTESİ